Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment

PURPOSE: Epidermal growth factor receptor (EGFR) T790M mutation serves as an important predictor of osimertinib efficacy. However, little is known about how it works among patients with various timings of T790M emergence and treatment. MATERIALS AND METHODS: Advanced EGFR-mutant lung adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Jeng-Sen, Yang, Tsung-Ying, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Huang, Yen-Hsiang, Su, Kang-Yi, Yu, Sung-Liang, Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192904/
https://www.ncbi.nlm.nih.gov/pubmed/29228521
http://dx.doi.org/10.4143/crt.2017.460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192904/
https://www.ncbi.nlm.nih.gov/pubmed/29228521
http://dx.doi.org/10.4143/crt.2017.460

Ejemplares similares